Owhofasa Agbedia, MD, MPH, FACP
@fasaagbedia
Hematologist/Medical Oncologist | Interest in hematological malignancies | Tweets/opinions are mine ≠ medical advice #CART #Lymphoma #lysm
ID: 1362315860
18-04-2013 16:14:29
344 Tweet
850 Takipçi
2,2K Takip Edilen
CONGRESS|#EHA2023 Matthew Frank Stanford Medicine discusses the safety and efficacy of CD22 CART therapy in pts with LBCL who have relapsed after CD19 CART therapy. The ORR and CR rates were 68% and 53%, respectively #lymphoma #lymsm #medicalcongress
MRD-NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS Mark Roschewski Foresight Diagnostics Inc. Jason Westin, MD FACP Ryan Lynch Stephen Opat NCI Center for Cancer Research MorphoSys onlinelibrary.wiley.com/doi/10.1002/ho…
“If you want to go fast go alone, if you want to go far, go together” I am incredibly proud to conclude this chapter alongside an immensely talented class of physicians. 🎉👩⚕️👨⚕️. The top of every mountain is the bottom of the next. Excited for the next phase MD Anderson Cancer Center
Navitoclax a B-cell lymphoma (BCL)-extra large (BCL-XL)/BCL-2 inhibitor for the treatment of MF | Kudos to Naveen Pemmaraju, MD and team👏🏾👏🏾
Are all cytopenias after CAR-T created equal? We explored that question using the phenotypes of post-CAR neutrophil recovery as a blueprint to examine the pathophysiology of hematotoxicity and study its prognostic impact. Out today Science Advances 🎉 science.org/doi/10.1126/sc…
Big news day in #lymsm #lymphoma ! Congratulations Katharine Lewis Chan Cheah et al for leading this massive international effort High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma ascopubs.org/doi/10.1200/JC…
Phase 1 study: Anti-CD37 CAR-T cells in rel/ref CD37+ B and T-cell lymphoma. N=5, 3/5 achieved CR. 3/5 had profound pancytopenia requiring alloHCT in 2 patients #CARTcell Matthew Frigault Dr Marcela Maus #lymsm #bmtsm ashpublications.org/blood/article-…